These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28825876)

  • 1. Safety of oral cholera vaccines during pregnancy in developing countries.
    Khan AI; Islam MT; Qadri F
    Hum Vaccin Immunother; 2017 Oct; 13(10):2245-2246. PubMed ID: 28825876
    [No Abstract]   [Full Text] [Related]  

  • 2. Cholera vaccine inactivated oral.
    Drugs R D; 1999 Sep; 2(3):193-4. PubMed ID: 10641223
    [No Abstract]   [Full Text] [Related]  

  • 3. Impaired immune response to natural infection as a correlate of vaccine failure in a field trial of killed oral cholera vaccines.
    Clemens J; Rao M; Sack D; Ahmed F; Khan MR; Chakraborty J; Kay B; Huda S; Yunus M; van Loon F
    Am J Epidemiol; 1995 Oct; 142(7):759-64. PubMed ID: 7572947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An oral cholera vaccine for travelers (Vaxchora).
    Med Lett Drugs Ther; 2016 Aug; 58(1502):113-4. PubMed ID: 27552209
    [No Abstract]   [Full Text] [Related]  

  • 5. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine.
    Cash RA; Music SI; Libonati JP; Craig JP; Pierce NF; Hornick RB
    J Infect Dis; 1974 Oct; 130(4):325-33. PubMed ID: 4443613
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults.
    Anh DD; Canh DG; Lopez AL; Thiem VD; Long PT; Son NH; Deen J; von Seidlein L; Carbis R; Han SH; Shin SH; Attridge S; Holmgren J; Clemens J
    Vaccine; 2007 Jan; 25(6):1149-55. PubMed ID: 17055622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.
    Trach DD; Cam PD; Ke NT; Rao MR; Dinh D; Hang PV; Hung NV; Canh DG; Thiem VD; Naficy A; Ivanoff B; Svennerholm AM; Holmgren J; Clemens JD
    Bull World Health Organ; 2002; 80(1):2-8. PubMed ID: 11884967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial.
    Cordero De Los Santos L; Feris-Iglesias J; Aloysia D'Cor N; Midde VJ; Patnaik BN; Thollot Y; Rasuli A; Desauziers E
    Hum Vaccin Immunother; 2018 Jun; 14(6):1403-1411. PubMed ID: 29470934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation and suppression of the proinflammatory immune response by Vibrio cholerae toxins.
    Satchell KJ
    Microbes Infect; 2003 Nov; 5(13):1241-7. PubMed ID: 14623020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine.
    Levine MM
    BMC Biol; 2010 Oct; 8():129. PubMed ID: 20920375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new oral vaccine candidate based on the microencapsulation by spray-drying of inactivated Vibrio cholerae.
    Año G; Esquisabel A; Pastor M; Talavera A; Cedré B; Fernández S; Sifontes S; Aranguren Y; Falero G; García L; Solís RL; Pedraz JL
    Vaccine; 2011 Aug; 29(34):5758-64. PubMed ID: 21683110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia.
    Desai SN; Akalu Z; Teshome S; Teferi M; Yamuah L; Kim DR; Yang JS; Hussein J; Park JY; Jang MS; Mesganaw C; Taye H; Beyene D; Bedru A; Singh AP; Wierzba TF; Aseffa A
    Am J Trop Med Hyg; 2015 Sep; 93(3):527-533. PubMed ID: 26078323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children.
    Suharyono ; Simanjuntak C; Witham N; Punjabi N; Heppner DG; Losonsky G; Totosudirjo H; Rifai AR; Clemens J; Lim YL
    Lancet; 1992 Sep; 340(8821):689-94. PubMed ID: 1355798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
    Raghava Mohan V; Raj S; Dhingra MS; Aloysia D'Cor N; Singh AP; Saluja T; Kim DR; Midde VJ; Kim Y; Vemula S; Narla SK; Sah B; Ali M
    PLoS One; 2019; 14(6):e0218033. PubMed ID: 31211792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholera vaccines: WHO position paper – August 2017.
    Wkly Epidemiol Rec; 2017 Aug; 92(34):477-98. PubMed ID: 28845659
    [No Abstract]   [Full Text] [Related]  

  • 17. Why is the oral cholera vaccine not considered an option for prevention of cholera in India? Analysis of possible reasons.
    Gupta SS; Bharati K; Sur D; Khera A; Ganguly NK; Nair GB
    Indian J Med Res; 2016 May; 143(5):545-51. PubMed ID: 27487997
    [No Abstract]   [Full Text] [Related]  

  • 18. PaxVax CVD 103-HgR single-dose live oral cholera vaccine.
    Levine MM; Chen WH; Kaper JB; Lock M; Danzig L; Gurwith M
    Expert Rev Vaccines; 2017 Mar; 16(3):197-213. PubMed ID: 28165831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular design of cholera vaccines.
    Manning PA
    Vaccine; 1992; 10(14):1015-21. PubMed ID: 1361701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation in tablets of a cholera whole cells inactivated vaccine candidate.
    Talavera A; Año G; Pino Y; Castaño J; Uribarri E; Riverón L; Gil S; Fernández S; Cedré B; Valmaseda T; Pérez JL; Infante JF; García L; Sierra G
    Vaccine; 2006 Apr; 24(16):3381-7. PubMed ID: 16460846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.